Jaguar Health, Inc. entered into a subscription agreement to issue 951 Series N Perpetual Preferred Stock at an issue price of $2,502.63 for the proceeds of $2,380,001.13 on September 9, 2025. The transaction is subject to shareholder approval. Securities will be offered pursuant to Regulation D. Holders of shares of Series N Preferred Stock (the ?Holders?) will not be entitled to receive any dividends on shares of Series N Preferred Stock and Series N Preferred Stock shall not be convertible into Common Stock.
Jaguar Health, Inc. announced that it expects to receive $2.380001 million in funding
Published on 09/09/2025
S&P Capital IQ
Share
© S&P Capital IQ -
2025
Share

















